coin-img-BTCBTC-3.07%coin-img-SOLSOL-1.78%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.31%coin-img-UBOXUBOX-27.45%coin-img-HYPEHYPE-2.45%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.76%coin-img-BTCBTC-3.07%coin-img-SOLSOL-1.78%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.31%coin-img-UBOXUBOX-27.45%coin-img-HYPEHYPE-2.45%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.76%coin-img-BTCBTC-3.07%coin-img-SOLSOL-1.78%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.31%coin-img-UBOXUBOX-27.45%coin-img-HYPEHYPE-2.45%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.76%coin-img-BTCBTC-3.07%coin-img-SOLSOL-1.78%coin-img-USDCUSDC-0.02%coin-img-XRPXRP-2.31%coin-img-UBOXUBOX-27.45%coin-img-HYPEHYPE-2.45%coin-img-ULTIMAULTIMA-0.08%coin-img-ETHETH-2.76%
user-avatar
CNBC TV18

Concord Biotech Q1 net profit rises 33% to ₹58.5 crore as revenue and margins improve

AI Market Summary
Concord Biotech reported strong FY2024 Q1 results with net profit up 33% YoY, revenue up 26%, and EBITDA margin expanding to 32%, indicating improved operating efficiency and product mix. The stock rose ahead of the release, reflecting positive expectations. While supportive for India's pharma theme, this is a single-company earnings update with limited read-through to broader global markets.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.56%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Concord Biotech reported fiscal 2024 first-quarter results for the period ended June 30, with net profit rising 33% year on year to ₹58.5 crore. Revenue from operations increased 26.2% to ₹257.4 crore. EBITDA climbed to ₹82.4 crore and the EBITDA margin improved to 32% from 30.1% a year earlier. The results point to stronger operating efficiency alongside improved margins.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.